Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

被引：0

作者：

Spelman, Lynda ^{[1
]}

Warren, Richard B. ^{[2
]}

Sofen, Howard ^{[3
]}

Imafuku, Shinichi ^{[4
]}

Blauvelt, Andrew ^{[5
]}

Toms, Jessica ^{[6
]}

Buck, Alex ^{[7
]}

Banerjee, Subhashis ^{[6
]}

Menter, Alan ^{[8
]}

Szepietowski, Jacek C. ^{[9
]}

机构：

[1] Verac Clin Res, Brisbane, Qld, Australia

[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England

[3] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[4] Fukuoka Univ Hosp, Fukuoka, Japan

[5] Oregon Med Res Ctr, Portland, OR USA

[6] Bristol Myers Squibb, New York, NY USA

[7] Cytel Inc, Bristol Myers Squibb, Dallas, TX USA

[8] Baylor Univ, Med Ctr, Waco, TX 76798 USA

[9] Wroclaw Med Univ, Wroclaw, Poland

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：28 / 28

页数：1

共 50 条

[1] DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Warren, R. B.
Sofen, H.
Imafuku, S.
Szepietowski, J.
Blauvelt, A.
Spelman, L.
Colston, E.
Toms, J.
Buck, A.
Banerjee, S.
Menter, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 841 - 841
[2] Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
Warren, Richard
Sofen, Howard
Imafuku, Shinichi
Szepietowski, Jacek C.
Blauvelt, Andrew
Spelman, Lynda
Toms, Jessica
Buck, Alex
Banerjee, Subhashis
Menter, Alan
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4230 - 4232
[3] Deucravacitinib (DEUC) Long-Term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program
Thaci, Diamant
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Szepietowski, Jacek
Spelman, Lynda
Passeron, Thierry
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Kisa, Renata
Banerjee, Subhashis
Menter, Alan
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 121
[4] DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Korman, N. J.
Passeron, T.
Gordon, K. B.
Okubo, Y.
Bagel, J.
Sofen, H.
Warren, R. B.
Bhatia, N.
Spelman, L.
Winthrop, K.
Hippeli, L.
Kisa, R. M.
Banerjee, S.
Thaci, D.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1774 - 1775
[5] Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
Lebwohl, Mark
Warren, Richard B.
Kircik, Leon
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Kisa, Renata M.
Banerjee, Subhashis
Menter, Alan
Thaci, Diamant
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[6] Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Szepietowski, Jacek C.
Spelman, Lynda
Passeron, Thierry
Vritzali, Eleni
Napoli, Andrew
Kisa, Renata M.
Buck, Alex
Banerjee, Subhashis
Thaci, Diamant
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (05) : 668 - 679
[7] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
Armstrong, April W.
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Morita, Akimichi
Paul, Carle
Papp, Kim A.
Colombo, Matthew J.
Scotto, Julie
Vaile, John
Zhuo, Joe
Vritzali, Eleni
Berger, Victoria
Schroeder, Georgene
Banerjee, Subhashis
Thaci, Diamant
Strober, Bruce
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
[8] Deucravacitinib Long-term Efficacy in Patients Originally Randomized to Placebo: 2-Year Results From the POETYK PSO Program
Lebwohl, Mark
Warren, Richard B.
Imafuku, Shinichi
Bagel, Jerry
Armstrong, April W.
Passeron, Thierry
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Thaci, Diamant
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[9] Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Warren, Richard
Armstrong, April W.
Imafuku, Shinichi
Morita, Akimichi
Paul, Carle
Augustin, Matthias
Passeron, Thierry
Kircik, Leon
Vritzali, Eleni
Scharnitz, Thomas
Schroeder, Georgene
Banerjee, Subhashis
Strober, Bruce
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2310 - 2312
[10] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren, Richard B.
Armstrong, April W.
Imafuku, Shinichi
Paul, Carle
Kircik, Leon
Colston, Elizabeth
Scharnitz, Thomas
Wang, Tao
Banerjee, Subhashis
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147

← 1 2 3 4 5 →